Brind.

Phio Pharmaceuticals Corp. is evaluating its drug PH-762 for the treatment of Merkel cell carcinoma and cutaneous squamous cell carcinoma.

2 reports, 1 independent Updated Fri 00:00
No new developments lately
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Phio Pharmaceuticals Corp. is evaluating its drug PH-762 for the treatment of Merkel cell carcinoma and cutaneous squamous cell carcinoma.

How it developed

Newest first. Tap a step to see who reported it.
  1. PH-762, which targets PD-1 via the INTASYL platform, is being advanced as a neoadjuvant treatment for CSCC.1 source
  2. Phio Pharmaceuticals Corp. is evaluating its drug PH-762 for two types of skin cancer.

Coverage

Newest first; wire copies grouped